Funding from Anglia Ruskin University is helping small firms' cutting-edge initiatives
Virtual reality therapy for people suffering from mental health disorders, using AI to manage demand on NHS services, and technology that listens to a child’s cough to assist early diagnoses are among the Essex innovations that have received thousands of pounds of funding from Arise Innovation Hubs – part of Anglia Ruskin University (ARU).
Sandwich, Kent, UK / 23 October 2024 / In a bid to enable future success and growth, ten entrepreneurial life science and technology businesses have begun the immersive Discovery Spark programme, with a prize package worth over £50,000 up for grabs.
Digital pathology is used within pathology, computer science and image analysis and is transforming how pathologists diagnose and research diseases. Within this article, we will conduct a deep dive into the benefits of digital pathology. While doing this, we will emphasise its impact on healthcare outcomes, research and education.
Read article here:
https://sourcebioscience.com/what-are-the-benefits-of-digital-pathology/
Stevenage, UK, 22 October 2024 - Laverock Therapeutics, a gene-silencing company with a uniquely powerful technology for the development of programmable advanced therapies to tackle major diseases, today announces it is to present new data on its innovative gene-silencing platform at the European Society of Gene & Cell Therapy (ESGCT) Conference in Rome 22-25 October.
CPI has fully opened its RNA Centre of Excellence to support the rising demand for RNA-based therapies and vaccines. The service offers comprehensive support, including plasmid DNA production, RNA transcription, purification, and formulation, alongside process development, analytics, and regulatory guidance.
At Broken String Biosciences, we are driving innovation in genome editing technologies to enable safer, more effective cell and gene therapies. Our mission is to advance the next generation of precise, safe, and efficient therapies through our cutting-edge technology platforms.
Our flagship technology, INDUCE-seq™, offers rapid and accurate DNA break mapping, providing critical insights into how genome editors interact with DNA. This data-driven approach helps unlock new editing targets and supports the development of life-saving therapies that are safer by design.
About Us:
Domainex is a multi-award winning integrated drug discovery CRO that has been setting the highest standards in drug discovery, with a particular emphasis on small molecule research, since 2001. We work in partnership with clients from a variety of sectors including academic, pharmaceutical, biotechnology and patient foundation organisations around the world. Our vision is to be the pre-eminent partner for innovative drug discovery services that improve the quality of life for people living with disease.
Domainex is a multi-award winning integrated drug discovery CRO that has been setting the highest standards in drug discovery, with a particular emphasis on small molecule research, since 2001. We work in partnership with clients from a variety of sectors including academic, pharmaceutical, biotechnology and patient foundation organisations around the world. Our vision is to be the pre-eminent partner for innovative drug discovery services that improve the quality of life for people living with disease.